A novel type of enzyme immunometric assay has been developed for a hep
tapeptide, BN 52080. This compound is a short C-terminal analogue of s
orbin and is under clinical evaluation for treatment of chronic diarrh
ea. In this solid-phase immobilized epitope immunoassay (SPIE-IA), the
peptide is first immunologically bound to polyclonal antibodies adsor
bed to a solid phase and then, after covalent immobilization with glut
araldehyde, is released from the antibody paratope by NaOH. The peptid
e linked to the solid phase is further quantified with a tracer consis
ting of the same antibodies purified by affinity chromatography and co
upled to acetylcholinesterase. This assay has a detection limit of 10
pg/ml and is therefore five times more sensitive than competitive enzy
me immunoassay using the same antibodies and BN 52080 coupled to acety
lcholinesterase as tracer. The assay is specific and allows direct mea
surement of peptide in human plasma after subcutaneous or intravenous
administration of 200 mu g of BN 52080 to volunteers.